NICE recommends lung drug

Pharma NICE Update NICE has recommended the use of Esbriet (pirfenidone) in final guidance for certain patients with idiopathic pulmonary fibrosis.

The treatment has been backed as an option for patients who have a forced vital capacity – the amount of air which can be forcibly exhaled after a deep breath – predicted between 50% and 80% of the normal level.

The Institute predicts that its guidance will see around 6,800 patients with the chronic lung condition becoming eligible to use the treatment.

The guidance also advises clinicians that patients should stop taking Esbriet if their disease continues to worsen.

Esbriet is manufactured by InterMune.